Literature DB >> 16687238

Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.

I Dimitrakopoulos1, C Magopoulos, D Karakasis.   

Abstract

Bisphosphonates are compounds used in the treatment of various metabolic and malignant bone diseases. In the last 2 years there has been a significant increase in referrals to the Department of Oral and Maxillofacial Surgery of patients with exposed necrotic jaw bone, diagnosed elsewhere as chronic refractory osteomyelitis of jaws, mostly after several teeth extractions. The only clinical feature in common for all the patients was the use of bisphosphonates in the treatment of bone diseases. A retrospective study was performed of 11 patients with necrotic bone lesions of the jaws of various extents referred to this Department from July 2003 to November 2004. The management of the patients included cessation of bisphosphonate therapy for 2-8 months and various surgical restorative procedures thereafter. Four patients (36%) presented with maxillary bone involvement, 6 (55%) had mandibular bone necrosis and 1 (9%) presented with necrosis at 3 quadrants. All patients had received bisphosphonate therapy for 6 months to 5 years. Biopsies from the necrotic lesions revealed no metastatic disease. One patient who was removed from bisphosphonate therapy for 8 months recovered completely, one other who was not removed from bisphosphonate therapy relapsed and for all the others, with cessation of bisphosphonate therapy for 2-6 months, the results were inconsistent. A new complication of bisphosphonate therapy administration, i.e. osteonecrosis of jaws, seems to be developing. The improved results after cessation of the medication should make clinicians reconsider the merits of the rampant use of bisphosphonates, while further investigation is needed to completely elucidate this complication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687238     DOI: 10.1016/j.ijom.2006.02.022

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  12 in total

1.  Bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Aliya Khan
Journal:  Can Fam Physician       Date:  2008-07       Impact factor: 3.275

Review 2.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

3.  Localized osteomyelitis of the mandible secondary to dental treatment: report of a case.

Authors:  Saeed Nezafati; Mohammad Ali Ghavimi; Amir Saeed Yavari
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2009-06-05

Review 4.  Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.

Authors:  Yusuf Farouk Suleman; Shabnum Meer; Russel Lurie
Journal:  Head Neck Pathol       Date:  2007-12-08

5.  A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.

Authors:  Jeannie Huang; Linda Meixner; Susan Fernandez; J Allen McCutchan
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

6.  Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.

Authors:  John H Wessel; Thomas B Dodson; Athanasios I Zavras
Journal:  J Oral Maxillofac Surg       Date:  2008-04       Impact factor: 1.895

Review 7.  Osteonecrosis of the jaws and bisphosphonates.

Authors:  David G Pendrys; Stuart L Silverman
Journal:  Curr Osteoporos Rep       Date:  2008-03       Impact factor: 5.096

Review 8.  Factors associated with osteonecrosis of the jaw among bisphosphonate users.

Authors:  Lisa M Hess; Joanne M Jeter; Marge Benham-Hutchins; David S Alberts
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

9.  Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases.

Authors:  W Park; N-K Kim; M-Y Kim; Y-M Rhee; H J Kim
Journal:  Osteoporos Int       Date:  2009-05-30       Impact factor: 4.507

10.  Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect.

Authors:  Ilke Coskun Benlidayi; Rengin Guzel
Journal:  ISRN Rheumatol       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.